Hou Sichuan

Dr. Hou Sichuan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
KWKongjia Wang
Kongjia Wang
YDYixin Ding
Yixin Ding
YLYunbo Liu
Yunbo Liu
MMMingyu Ma
Mingyu Ma
JWJi Wang
Ji Wang
HSHou Sichuan
Hou Sichuan
Clear cell renal cell carcinoma (ccRCC) is a commonly occurring and highly aggressive urological malignancy characterized by a significant mortality rate. Current therapeutic options for advanced ccRCC are limited, necessitating the discovery of novel biomarkers and therapeutic targets. Carboxypeptidase A4 (CPA4) is a zinc‐containing metallocarboxypeptidase with implications in various cancer types, but its role in ccRCC remains unexplored. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized in order to investigate the differential expression patterns of CPA4. The expression of CPA4 in ccRCC patients was further verified using immunohistochemical (IHC) examination of 24 clinical specimens. A network of protein–protein interactions (PPI) was established, incorporating CPA4 and its genes that were expressed differentially. Functional enrichment analyses were conducted to anticipate the contribution of CPA4 in the development of ccRCC. To validate our earlier study, we conducted real‐time PCR and cell functional tests on ccRCC cell lines. Our findings revealed that CPA4 is overexpressed in ccRCC, and the higher the expression of CPA4, the worse the clinical outcomes such as TNM stage, pathological stage, histological grade, etc. Moreover, patients with high CPA4 expression had worse overall survival, disease‐specific survival and progress‐free interval than patients with low expression. The PPI network analysis highlighted potential interactions contributing to ccRCC progression. Functional enrichment analysis indicated the involvement of CPA4 in the regulation of key pathways associated with ccRCC development. Additionally, immune infiltration analysis suggested a potential link between CPA4 expression and immune response in the tumour microenvironment. Finally, cell functional studies in ccRCC cell lines shed light on the molecular mechanisms underlying the role of CPA4 in promoting ccRCC formation. Overall, our study unveils CPA4 as a promising biomarker with prognostic potential in ccRCC. The identified interactions and pathways provide valuable insights into its implications in ccRCC development and offer a foundation for future research on targeted therapies. Further investigation of CPA4's involvement in immune responses may contribute to the development of immunotherapeutic strategies for ccRCC treatment.

4 December 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
SLShuo Liu
Shuo Liu
BZBowen Zhang
Bowen Zhang
BWBowen Weng
Bowen Weng
XLXiangqiang Liu
Xiangqiang Liu
HSHou Sichuan
Hou Sichuan
Purpose This study compared perioperative outcomes of robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) through the PADUA score as well as assessed the predictive value of the PADUA score and the Mayo Adhesive Probability (MAP) score for postoperative complications. Methods Totally 196 patients suffering from RAPN or LPN for renal tumors were reviewed retrospectively. Patients were categorized by PADUA score (low-, moderate-, high-complexity) and MAP score (low-, intermediate-, high-grade). Evaluated outcomes included operative time (OT), warm ischemia time (WIT), estimated blood loss (EBL), drainage duration, postoperative length of stay, and absolute change in estimated glomerular filtration rate (eGFR) at three months post-surgery, along with intra- and postoperative complications. Results RAPN outperformed LPN in the low-complexity group by lowering WIT (P = 0.022) and absolute eGFR change (P = 0.011). For moderate-complexity group, RAPN reduced WIT (P = 0.021), absolute eGFR change (P = 0.027), and postoperative length of stay (P = 0.008). In the high-complexity group, RAPN reduced OT (P = 0.015), WIT (P = 0.023), EBL (P = 0.036), absolute eGFR change (P = 0.024), and postoperative length of stay (P = 0.019). Drainage duration showed no significant differences across groups (P = 0.442, P = 0.327, P = 0.260). RAPN incurred significantly higher total costs than LPN across groups (P < 0.001). ROC analysis suggested PADUA and MAP scores as reliable predictors of postoperative complications in RAPN (AUC = 0.880,0.828) and LPN (AUC = 0.757,0.702). Conclusion RAPN provides significant advantages over LPN in managing complex renal tumors (PADUA score ≥ 10), significantly in reducing OT, WIT, EBL, and absolute eGFR change at three months post-surgery, while minimizing postoperative stay. The PADUA and MAP scores are valuable in predicting postoperative complication. Trial registration number and date of registration Retrospectively registered.

30 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MMMingyu Ma
Mingyu Ma
SWShufei Wang
Shufei Wang
KWKongjia Wang
Kongjia Wang
BJBo Jiang
Bo Jiang
JLJingwen Li
Jingwen Li
HSHou Sichuan
Hou Sichuan
Bladder cancer (BLCA) and diabetes mellitus (DM) are two prevalent diseases that may share molecular mechanisms, suggesting potential links between metabolic disorders and cancer. Using bioinformatics approaches, we integrated multiple databases to identify common genes between BLCA and DM, screening for potential biomarkers. CXCL12 (C-X-C motif chemokine 12, also known as stromal cell-derived factor 1 , SDF-1) was ultimately identified as a key gene, followed by comprehensive analyses including immune infiltration analysis, functional enrichment analysis, survival analysis, clinicopathological correlation analysis, TIDE immune prediction scoring, and immunophenoscore (IPS) scoring comparison. The results indicate that CXCL12 is associated with altered immune cell function and tumor characteristics under elevated blood glucose levels, influencing the tumor microenvironment and promoting disease progression. The results elucidate the molecular underpinnings of BLCA and DM, establishing a basis for subsequent investigations into common mechanisms and the formulation of targeted therapeutic approaches. Research on shared biomarkers, such as CXCL12, between metabolic diseases and tumors aids in the precise prevention and control of comorbidities’ adverse effects on tumor progression. This approach significantly reduces the health burden linked to comorbidities.

1 February 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
KWKongjia Wang
Kongjia Wang
SWShufei Wang
Shufei Wang
YDYixin Ding
Yixin Ding
ZKZengshun Kou
Zengshun Kou
BJBo Jiang
Bo Jiang
HSHou Sichuan
Hou Sichuan
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased susceptibility to cancer, including bladder urothelial carcinoma (BLCA). This study investigates the shared molecular mechanisms and gene signatures between SLE and BLCA, shedding light on potential biomarkers and therapeutic targets. Methods: We compiled gene datasets related to SLE and BLCA from various databases and identified common genes. Differential gene expression analysis, protein-protein interaction networks, and hub gene identification were performed. We studied functional enrichment, immune infiltration, and transcription factor/miRNA regulation networks. We also explored gene-disease interactions and protein-chemical/drug networks. Hub gene expression levels and diagnostic values were validated in TCGA and GEO databases. Prognostic analysis was performed on the core gene MMP9 in the TCGA-BLCA database to study its prognostic value. Finally, the mRNA expression of MMP9 was verified in bladder cancer cell lines and BLCA patient blood. The diagnostic value of MMP9 for BLCA was verified by receiver operating characteristic(ROC) curve analysis of the expression of MMP9 in patients’ blood. Results: We identified 524 common genes between SLE and BLCA, enriched in pathways related to apoptosis and cytokine regulation. Immune infiltration analysis for two diseases. Transcription factors and microRNAs were implicated in regulating these common genes. The gene-disease network linked hub genes with various diseases, emphasizing their roles in autoimmune disease and cancer. Protein-chemical/drug networks highlighted potential treatment options. Finally, our study found that MMP9 is a potential therapeutic target with diagnostic and prognostic value and Immune-related biomarkers in patients with BLCA and SLE. Conclusion: Our study reveals shared molecular mechanisms, genetic signatures, and immune infiltrates between SLE and BLCA. MMP9 emerges as a potential diagnostic and prognostic biomarker in BLCA, warranting further investigation. These findings provide insights into the pathogenesis of SLE-associated BLCA and may guide future research and therapeutic strategies.

17 January 2023 in Frontiers in Chemistry
Verified
Journal Article
Open access
QWQiang Wang
Qiang Wang
BLBaohu Li
Baohu Li
WZWenkai Zhang
Wenkai Zhang
ZLZhuoyue Li
Zhuoyue Li
BJBo Jiang
Bo Jiang
Chong QinChong Qin
Chong Qin
Bladder cancer is the most common malignancy of the urinary system. Efforts to identify innovative and effective therapies for bladder cancer are urgently needed. Recent studies have identified the BRD4 protein as the critical factor in regulation of cell proliferation and apoptosis in bladder cancer, and it shows promising potential for pharmacologic treatment against bladder cancer. In this study, we have evaluated the biological function of QCA570, a novel BET degrader, on multiple bladder cancer cells and explore its underlying mechanisms. QCA570 potently induces degradation of BRD4 protein at nanomolar concentrations, with a DC50 of ∼ 1 nM. It decreases EZH2 and c-MYC levels by transcriptional suppression and protein degradation. Moreover, the degrader significantly induces cell apoptosis and cycle arrest and shows antiproliferation activity against bladder cancer cells. These findings support the potential efficacy of QCA570 on bladder cancer.

1 April 2021 in Asian Journal of Surgery
Verified
Journal Article
Open access
SSShizhang Song
Shizhang Song
XLXin Liang
Xin Liang
BJBo Jiang
Bo Jiang
HSHou Sichuan
Hou Sichuan